Page 1797 - Williams Hematology ( PDFDrive )

1772 Part XI: Malignant Lymphoid Diseases <CN>: <ct> PB

625. Dispenzieri A, Buadi F, Laumann K, et al: Activity of pomalidomide in patients with 637. Landgren O: Monoclonal gammopathy of undetermined significance and smoldering
immunoglobulin light-chain amyloidosis. Blood 119:5397–5404, 2012. multiple myeloma: Biological insights and early treatment strategies. Hematology Am
626. Landau HH, Hassoun H, Cohen AD, et al: Adjuvant bortezomib and dexamethasone Soc Hematol Educ Program 2013:478–487, 2013.
following high-risk melphalan and stem cell transplant in systemic AL amyloidosis 638. Harousseau JL, Attal M, Avet-Loiseau H, et al: Bortezomib plus dexamethasone is supe-
[abstract]. J Clin Oncol 27:Abstract 8540, 2009. rior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior
627. Venner CP, Lane T, Foard D, et al: Cyclophosphamide, bortezomib, and dexamethasone to autologous stem-cell transplantation in newly diagnosed multiple myeloma: Results
therapy in AL amyloidosis is associated with high clonal response rates and prolonged of the IFM 2005–01 phase III trial. J Clin Oncol 28:4621–4629, 2010.
progression-free survival. Blood 119:4387–4390, 2012. 639. Reeder CB, Reece DE, Kukreti V, et al: Cyclophosphamide, bortezomib and dexametha-
628. Comenzo RL, Gertz MA: Autologous stem cell transplantation for primary systemic sone induction for newly diagnosed multiple myeloma: High response rates in a phase
amyloidosis. Blood 99:4276–4282, 2002. II clinical trial. Leukemia 23:1337–1341, 2009.
629. Alexanian R: Localized and indolent myeloma. Blood 56:521–525, 1980. 640. Hulin C, Facon T, Rodon P, et al: Efficacy of melphalan and prednisone plus thalid-
630. Kyle RA, Greipp PR: Smoldering multiple myeloma. N Engl J Med 302:1347–1349, 1980. omide in patients older than 75 years with newly diagnosed multiple myeloma: IFM
631. Dimopoulos MA, Moulopoulos A, Smith T, et al: Risk of disease progression in asymp- 01/01 trial. J Clin Oncol 27:3664–3670, 2009.
tomatic multiple myeloma. Am J Med 94:57–61, 1993. 641. San Miguel JF, Schlag R, Khuageva NK, et al: Persistent overall survival benefit and no
632. Mateos MV, Hernandez MT, Giraldo P, et al: Lenalidomide plus dexamethasone for increased risk of second malignancies with bortezomib-melphalan-prednisone versus
high-risk smoldering multiple myeloma. N Engl J Med 369:438–447, 2013. melphalan-prednisone in patients with previously untreated multiple myeloma. J Clin
633. Rajkumar SV, Larson D, Kyle RA: Diagnosis of smoldering multiple myeloma. N Engl J Oncol 31:448–455, 2013.
Med 365:474–475, 2011. 642. Richardson PG, Xie W, Jagannath S, et al: Phase II trial of lenalidomide, bortezomib,
634. Larsen JT, Kumar SK, Dispenzieri A, et al: Serum free light chain ratio as a biomarker and dexamethasone in patients (pts) with relapsed and relapsed/refractory multiple
for high-risk smoldering multiple myeloma. Leukemia 27:941–946, 2013. myeloma (MM): Updated efficacy and safety data after >2 years of follow-up. Blood
635. Hillengass J, Fechtner K, Weber MA, et al: Prognostic significance of focal lesions in (ASH Annual Meeting Abstracts) 116:Abstract 3049, 2010.
whole-body magnetic resonance imaging in patients with asymptomatic multiple mye- 643. San Miguel J, Weisel K, Moreau P, et al: Pomalidomide plus low-dose dexametha-
loma. J Clin Oncol 28:1606–1610, 2010. sone versus high-dose dexamethasone alone for patients with relapsed and refractory
636. Hillengass J, Landgren O: Challenges and opportunities of novel imaging techniques multiple myeloma (MM-003): A randomised, open-label, phase 3 trial. Lancet Oncol
in monoclonal plasma cell disorders: Imaging “early myeloma.” Leuk Lymphoma 54: 14:1055–1066, 2013.
1355–1363, 2013.

Kaushansky_chapter 107_p1733-1772.indd 1772 9/21/15 12:36 PM